JP2024505887A5 - - Google Patents

Info

Publication number
JP2024505887A5
JP2024505887A5 JP2023545274A JP2023545274A JP2024505887A5 JP 2024505887 A5 JP2024505887 A5 JP 2024505887A5 JP 2023545274 A JP2023545274 A JP 2023545274A JP 2023545274 A JP2023545274 A JP 2023545274A JP 2024505887 A5 JP2024505887 A5 JP 2024505887A5
Authority
JP
Japan
Prior art keywords
particle according
item
polynucleotide sequence
cell surface
sequence encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023545274A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024505887A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/013947 external-priority patent/WO2022164935A1/en
Publication of JP2024505887A publication Critical patent/JP2024505887A/ja
Publication of JP2024505887A5 publication Critical patent/JP2024505887A5/ja
Pending legal-status Critical Current

Links

JP2023545274A 2021-01-27 2022-01-26 抗cd19キメラ抗原受容体を発現する細胞を生成するためのレンチウイルス Pending JP2024505887A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163142347P 2021-01-27 2021-01-27
US63/142,347 2021-01-27
US202163185765P 2021-05-07 2021-05-07
US63/185,765 2021-05-07
PCT/US2022/013947 WO2022164935A1 (en) 2021-01-27 2022-01-26 Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor

Publications (2)

Publication Number Publication Date
JP2024505887A JP2024505887A (ja) 2024-02-08
JP2024505887A5 true JP2024505887A5 (cg-RX-API-DMAC10.html) 2025-01-22

Family

ID=80624056

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023545274A Pending JP2024505887A (ja) 2021-01-27 2022-01-26 抗cd19キメラ抗原受容体を発現する細胞を生成するためのレンチウイルス

Country Status (10)

Country Link
US (1) US20240141375A1 (cg-RX-API-DMAC10.html)
EP (1) EP4284821A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024505887A (cg-RX-API-DMAC10.html)
KR (1) KR20230143150A (cg-RX-API-DMAC10.html)
AU (1) AU2022212952A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023014980A2 (cg-RX-API-DMAC10.html)
CA (1) CA3206009A1 (cg-RX-API-DMAC10.html)
IL (1) IL304506A (cg-RX-API-DMAC10.html)
MX (1) MX2023008831A (cg-RX-API-DMAC10.html)
WO (1) WO2022164935A1 (cg-RX-API-DMAC10.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
WO2019144095A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Car t細胞療法のための配列決定法
SG11202009975TA (en) 2018-04-12 2020-11-27 Umoja Biopharma Inc Viral vectors and packaging cell lines
US12419913B2 (en) 2019-02-08 2025-09-23 Dna Twopointo, Inc. Modification of CAR-T cells
EP4045663A2 (en) * 2019-10-16 2022-08-24 Umoja Biopharma, Inc. Retroviral vector for univeral receptor therapy
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2024044557A1 (en) * 2022-08-23 2024-02-29 The Regents Of The University Of California Compositions and methods for targeted delivery of crispr-cas effector polypeptides
EP4602174A1 (en) 2022-10-13 2025-08-20 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
KR20250120449A (ko) * 2022-11-04 2025-08-08 우모자 바이오파마 인코포레이티드 폴리뉴클레오티드 구축물 및 관련 바이러스 벡터 및 방법
CN120457212A (zh) * 2022-11-04 2025-08-08 优莫佳生物制药股份有限公司 展示融合分子的慢病毒颗粒及其用途
WO2024216227A1 (en) * 2023-04-12 2024-10-17 Vyriad Cd3-redirected vectors, components thereof, and uses of the vectors and components thereof
EP4694916A1 (en) 2023-04-14 2026-02-18 SOTIO Biotech Inc. Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists
WO2024215987A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
WO2024220598A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Lentiviral vectors with two or more genomes
EP4702034A1 (en) 2023-04-27 2026-03-04 Miltenyi Biotec B.V. & Co. KG Pseudotyped retroviral vector particle with anti-cd3 display
WO2024238153A1 (en) * 2023-05-15 2024-11-21 Umoja Biopharma, Inc. Lentiviral delivery of anti-cd20 chimeric antigen receptors
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2025078492A1 (en) 2023-10-13 2025-04-17 Miltenyi Biotec B.V. & Co. KG Cd3-targeted nipah-pseudotyped lentiviral vector particles
WO2025102013A1 (en) * 2023-11-10 2025-05-15 Vyriad Rhabdovirus g proteins having one or more cysteine-rich regions and uses thereof
WO2025176853A1 (en) 2024-02-22 2025-08-28 Miltenyi Biotec B.V. & Co. KG Cd4- or cd8-targeted retroviral vector particles for generation of cells expressing a bispecific chimeric antigen receptor
WO2025212519A1 (en) 2024-04-01 2025-10-09 Moonlight Bio, Inc. Dll3 binding proteins and uses thereof
WO2026051968A1 (zh) * 2024-09-04 2026-03-12 深圳易慕峰生物科技股份有限公司 一种新型病毒颗粒及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
JP3866760B2 (ja) 1993-02-22 2007-01-10 ザ ロックフェラー ユニバーシティ 一過性トランスフェクションによる高力価のヘルパーフリーのレトロウイルスの生産
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5948893A (en) 1996-01-17 1999-09-07 The United States Of America As Represented By The Secretary Of The Navy Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
US9434928B2 (en) 2011-11-23 2016-09-06 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
WO2013148327A1 (en) 2012-03-26 2013-10-03 The Regents Of The University Of California Nipah virus envelope psuedotyped lentiviruses and methods of their use
WO2013188693A1 (en) * 2012-06-15 2013-12-19 Imaginab, Inc. Antigen binding constructs to cd3
EP3027204B1 (en) * 2013-07-29 2022-01-05 2seventy bio, Inc. Multipartite signaling proteins and uses thereof
WO2015090229A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
GB201503500D0 (en) 2015-03-02 2015-04-15 Ucl Business Plc Cell
CN108884460B (zh) * 2016-03-19 2023-04-28 埃克苏马生物技术公司 淋巴细胞转导及其扩增调节的方法与组合物
WO2019055946A1 (en) * 2017-09-18 2019-03-21 F1 Oncology, Inc. METHODS AND COMPOSITIONS FOR THE GENETIC MODIFICATION AND EXPANSION OF LYMPHOCYTES AND THE REGULATION OF THE ACTIVITY THEREOF
CA3045667A1 (en) 2016-12-13 2018-06-21 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
CN109535257B (zh) 2017-09-22 2021-05-28 同润生物医药(上海)有限公司 新型双特异性cd3/cd19多肽复合物
PT3684786T (pt) 2017-09-22 2024-10-30 Centre Nat Rech Scient Glicoproteína mutante do vírus da estomatite vesicular
WO2019118885A1 (en) * 2017-12-14 2019-06-20 Bluebird Bio, Inc. Nkg2d daric receptors
SG11202009975TA (en) 2018-04-12 2020-11-27 Umoja Biopharma Inc Viral vectors and packaging cell lines
CA3091490A1 (en) * 2018-04-27 2019-10-31 Seattle Children's Hospital (dba Seattle Children's Research Institute) Rapamycin resistant cells
EP3884058A1 (en) 2018-11-21 2021-09-29 Umoja Biopharma, Inc. Multicistronic vector for surface engineering lentiviral particles

Similar Documents

Publication Publication Date Title
Li et al. Increasing the safety and efficacy of chimeric antigen receptor T cell therapy
AU2018204209B2 (en) Method and compositions for cellular immunotherapy
JP2024149496A (ja) 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法
Jackson et al. Driving CAR T-cells forward
JP7360174B2 (ja) ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
Hudecek et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells
Nasiri et al. T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts
JP7288503B2 (ja) 改変された抗cd19 car-t細胞
Muhammad et al. CAR T-cells for cancer therapy
Stern et al. CAR T cell therapy progress and challenges for solid tumors
CN108276493A (zh) 一种新型嵌合抗原受体及其应用
Murad et al. Advances in the use of natural receptor-or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies
JP2022528030A5 (cg-RX-API-DMAC10.html)
EP3525805A1 (en) Compositions and methods for modulating the immune system
CN114437218B (zh) 靶向cd276的嵌合抗原受体以及包含其的免疫细胞
JP2024519335A (ja) がん免疫療法のための投薬レジメン
JP2024508808A5 (cg-RX-API-DMAC10.html)
WO2018045034A1 (en) Chimeric antigen receptors having gitr intracellular domain as co-stimulatory domain
Haist et al. Engineering a single-chain variable fragment of cetuximab for CAR T-cell therapy against head and neck squamous cell carcinomas
KR20190104920A (ko) 항-코티닌 키메릭 항원 수용체를 발현하는 자연살해 세포
CN113474012B (zh) Epcam抗体和epcam-car-t细胞
Hayashi et al. A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells
WO2020176897A1 (en) Chimeric antigen receptors and uses thereof
CN118786142A (zh) 用于治疗肿瘤的ror1 car或ror1/cd19双car t细胞
CN102584999A (zh) 靶向人vegfr-1的基因工程化淋巴细胞及其制备方法和用途